[Buprenorphine in the analgesic treatment of patients subjected to bladder mapping].
Experience with 20 patients suffering from prior papillary neoplasia of the bladder, already treated with TUR and then subjected to control vesical mapping exploiting the analgesic effect of a new drug buprenorphine hydrochloride administered i.v. is reported. Changes in cardiorespiratory variables are examined. The data show that buprenorphine offers good pain tolerance; the absence of respiratory depression suggests that it could be used on a larger scale in patients suffering from cardiorespiratory pathology undergoing multiple vesical biopsies.
Altomare
M
M
Dell'Olio
P
P
D000368:Aged; D000369:Aged, 80 and over; D000700:Analgesics / Q000009:adverse effects / Q000627:therapeutic use*; D001706:Biopsy; D002047:Buprenorphine / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D002291:Carcinoma, Papillary / Q000473:pathology*; D003558:Cystoscopy; D004341:Drug Evaluation; D005260:Female; D006801:Humans; D007262:Infusions, Intravenous; D008297:Male; D008875:Middle Aged; D001749:Urinary Bladder Neoplasms / Q000473:pathology*
D000700:Analgesics; D002047:Buprenorphine
La buprenorfina nel trattamento analgesico di pazienti da sottoporre a "mapping" vescicale.